Advances in Heart Failure - Is It Time to Redefine Patient Selection for Sodium-Glucose Co-transporter 2 Inhibitors?
Published: 09 October 2020
16m 28sPart 4 Q&A Discussion
This educational symposium was originally broadcast as part of the ESC 2020 Digital Congress.
The programme focuses on summarising recent data on SGLT2 inhibitors showing reductions in CV risk, HF hospitalisations and mortality, as well as improved quality-of-life. The expert panel also discuss how these agents should be introduced into clinical practice and contemporary heart failure guidelines for both diabetics and non-diabetics.
- Discuss Current SGLT2 Data and Guideline Recommendations for Utilization in Heart Failure
- Evaluate Emerging Data on the Treatment of Heart Failure with SGLT2 Inhibitors
- Understand the Implications of Emerging Data on the Treatment of Heart Failure With SGLT2 Inhibitors
More from this programme
SGLT2s as a Heart Failure Drug – How Did We Get Here?
Emerging Data SGLT2 Inhibitors in Heart Failure
Guidelines and Practice Implications
Follow-up Peer-to Peer Discussion
Martin R Cowie
Professor of Cardiology
Martin Cowie is Professor of Cardiology at King's College London, and Honorary Consultant Cardiologist at the Royal Brompton Hospital, London, UK. Prof Cowie chairs the Clinical Practice Committee of the British Cardiac Society and sits on the UK Department of Health’s Primary Care and Heart Failure Implementation Board.
Prof Cowie's research interests focus on health technology assessment and delivery of efficient and effective care for patients with heart failure, with a focus on diagnostics, drugs, and devices. He has had a longstanding interest in evaluating remote monitoring and other digital technologies in heart failure.
Prof Cowie’s studies and reviews have been published in a variety of peer-reviewed journals, including The Lancet, European Heart Journal, British Medical Journal, Heart and International Journal of Cardiology. He is a member of the editorial boards of Heart, The British Journal of Diabetes and…